Clinical disorders affecting mesopic vision by Petzold, A & Plant, GT
Clinical disorders affecting mesopic vision
A Petzold GT Plant
19.02.2006
Abstract
Vision in the mesopic range is affected by a number of inher-
ited and acquired clinical disorders. Here we review these condi-
tions and summarize the historical background, describe the clinical
characteristics alongside the genetic basis and molecular biological
mechanisms giving rise to rod and cone dysfunction relevant to twi-
light vision. The current diagnostic gold standards for each disease
are discussed and curative and symptomatic treatment strategies are
summarized.
Keywords: Autoimmune-related retinopathy and optic neuropathy (AR-
RON) syndrome, Bothnia dystrophy, cancer associated retinopathy, con-
genital stationary night blindness (CSNB), enhanced S–cone syndrome
(ESCS), fundus albipunctatus, melanoma associated retinopathy, New-
foundland rod-cone dystrophy, Oguchi disease, retinitis pigmentosa (RP),
retinitis punctata albescens, Sorsby fundus dystrophy, vitamin A deﬁciency
(VAD).
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1 Introduction
The visual system allows us to see over a remarkable range of illumination.
In fact, the visual system covers about 11 log10 units change in illumination
(Stockman and Sharpe this issue). We can adapt to see in bright sun light
relying purely on the cone system as well as in near complete darkness by
switching to the more sensitive rod system. The transition from photopic
(light) to scotopic (dark) vision is part of what is known as dark-adaptation.
Mesopic vision refers to visual function at certain light levels (twilight) at
which both the cone- and rod–system are active. Mesopic vision covers
about 32 to 0,0032 Candela per centimeter square (cd/m2). It is important
to remember that dark adaptation may take up to 40 minutes achieve full
sensitivity. Mesopic vision depends on both the external light level and the
speed of the biochemical processes providing the energy to turn the rod–
system fully on. Problems in mesopic vision are related to a pathological
transition from photopic to scotopic vision and may present clinically as
night blindness. The importance of rod function in mesopic conditions is
exempliﬁed by the fact that the contrast sensitivity of the rod system is
highest at light levels where cones are also still contributing to vision.
The term “night blindness” was introduced by Brodley and, though not
strictly accurate, is now in common use (Bordley, 1908). Alternative used
terms include “nyctalopia” (seeing at night, preferred in the French liter-
ature) or “hemeralopia” (seeing in the day). Strictly speaking nyctalopia
means day blindness, e.g. in cone monochromacy. There is much con-
troversy around the correct use for these terms with the Anglo–Saxon lit-
erature directly opposing the French literature (Duke-Elder, 1963; Skinner,
1970; Brouzas et al., 2001). In this review we refer to “impaired night vi-Review: mesopic vision and disease 4
sion” when we use the term “night blindness”.
In developed societies photopic conditions extend beyond the daylight
hours. That is to say many of us will rarely employ scotopic vision and
paracentral vision in the mesopic range is only needed under certain cir-
cumstances. One of the most important situations in which most of us still
rely on mesopic vision (rods and cones are active) is driving. There are
however certain work environments, leisure and sport activities were pe-
ripheral vision and hence rod signals are important, even at high levels of
scene luminance e.g., 10 cd/m2.
Vision in the mesopic range can be impaired in a number of diseases,
some of which are inherited and others are acquired. Here we review
these disorders and try to differentiate how they may affect mesopic vision
rather than pure rod (scotopic) vision. Additionally, we discuss how cone
dysfunction may also impair the early transition from photopic to mesopic
vision. Finally we propose a short guideline for investigating these patients
including the cardinal clinical features and history, the relevant investiga-
tions and treatment options.
2 Reduced vision in the mesopic range due to
rod dysfunction
Here we review the human conditions in which rod dysfunction leads to
slow dark adaptation and consequently to impaired vision in the mesopic
range. It is worth remembering that although the biochemical processes
driving rod function may be slowed due to defective enzymes, in many
instances the cellular metabolism permits adaptation such that normal rod
function may be observed after prolonged periods of dark adaption.Review: mesopic vision and disease 5
2.1 Hereditary conditions
A genetic mutation affecting any single protein or enzyme involved in the
retinoid processing cycle potentially causes retinal disease (reviewed by
Lamb and Pugh (Lamb and Pugh EN, 2004)). The ﬁve diseases relevant to
the present review are retinitis pigmentosa, retinitis pigmentata alibscens,
Bothnia dystrophy (BD), fundus albipunctatus, Congenital stationary night
blindness and Oguchi disease.
Retinitis pigmentosa comprises the largest group and three genetically
distinct variants, retinitis punctata albescens, Bothnia dystrophy, and New-
foundland rod-cone dystrophy will be discussed separately.
Retinitis pigmentosa (RP) Retinitis pigmentosa (RP), a clinically and
genetically heterogeneous group of disorders, is the most common hered-
itary cause for visual impairment in all age groups. It has a prevalence of
approximately 1:3500 (Pagon, 1988; Phelan and Bok, 2000).
The classical symptoms of night blindness at early age and bilateral
peripheral VF loss are predominantly observed in patients with rod–cone
RP. Although macular vision is relatively preserved, cone degeneration
in the later phases of the disease will affect central VA and day vision.
Progression to legal blindness may happen as early as in the third or as
late as in the sixth decade (Berson, 1996). Complete blindness occurs in
a proportion of RP patients. It is not possible to predict speed and extent
of visual failure.
Patients who present with loss of central vision, night blindness and VF
loss are likely to suffer from cone–rod dystrophy/degeneration, a RP allied
disease (Phelan and Bok, 2000).
The age of onset of symptoms is related to the mode of inheritanceReview: mesopic vision and disease 6
with children being more likely to suffer from X–linked RP, whilst younger
to older adults are more likely to suffer from autosomal recessive or auto-
somal dominant RP, respectively (Weleber, 1994). The increasing number
of RP genes (Hims et al., 2003; Delyfer et al., 2004) is regularly updated on
RetNet (www.sph.uth.tmc.edu/Retnet). The classiﬁcation of these genes
into functional classes is complex. Phelan and Bok classiﬁed these into
7 main functional groups (1) the visual cascade, (2) the visual cycle, (3)
tetraspanins, (4) photoreceptor cell transcription factors, (5) catabolic func-
tions in the retina, (6) mitochondrial genes and (7) genes of yet unknown
function (for review see (Phelan and Bok, 2000) and references therein).
Kalloniatis and Fletcher recently reviewed the underlying biological mech-
anisms (Kalloniatis and Fletcher, 2004).
Fundus examination shows the typical picture of a mottled or granular
appearance of the retina early in the disease (Figure 1) which develops
into bone–spicule pigmentary deposits overlying the depigmented retina
(Figure 2) (Phelan and Bok, 2000). There is some variation in the appear-
ance of pigmentary changes and window–like holes through the RPE are
observed as are hypopigmentation, translucence and accumulation of pig-
ment deposits of circular shape. Retinal atrophy results in attenuation of
the retinal blood vessels and a pale disc due to loss of the nerve ﬁbre layer
(Phelan and Bok, 2000; Weleber, 1994; Heckenlively, 1988).
Electroretinography plays a central role in the diagnosis of RP (see
(Heckenlively, 1988; Marmor and Zrenner, 1998-99) and references therein).
In the classical picture of rod degeneration abnormalities in the scotopic
ERG precede those in the photopic ERG. In contrast in RP allied diseases
presenting with cone–rod dystrophy the photopic ERG becomes abnormal
ﬁrst (Phelan and Bok, 2000). Occasionally a disproportional disruption ofReview: mesopic vision and disease 7
Figure 1: Retinitis pigmentosa, in a child showing the early development
of a pigmentary retinopathy with optic disc pallor and retinal arteriolar nar-
rowing (reprocuced with permission from reference (Spalton et al., 2005)).Review: mesopic vision and disease 8
Figure 2: Retinitis pigmentosa, the fundus appearance in early disease
may be variable sometimes including mild pigment epithelial atrophy in the
mid–periphery and small white dots at the level of the RPE. The typical
bone spicule pigment deposition is typically seen later in the disease. (re-
produced with permission from reference (Spalton et al., 2005)).Review: mesopic vision and disease 9
the photoreceptor component of the ERG b–wave is observed represented
as an electronegative ERG. An absent ERG response is seen in the end–
stages of the disease. There are anecdotal reports of an abnormal ERG
preceding the onset of clinical symptoms later in life. In those cases where
parents are affected by RP, but no gene has yet been identiﬁed this may
occasionally be an issue for counseling and investigating the children.
There is no curative therapy available in RP yet. Low vision man-
agement remains one of the most valuable symptomatic treatment op-
tions (Weiss, 1991). This includes providing best refraction. The use of
electronic means of magniﬁcation using special settings for the computer
screen is extremely valuable and complements the common magnifying
glass. Where a complaint of glare is related to cataract this is amenable
to surgery. Glare may also be controlled by spectacle glasses incorpo-
rationg short–wavelength ﬁlters. Care has to be taken that appropriate
levels of illumination are provided for visual tasks. A range of VF enhanc-
ing device have been used with a varying degree of success and other
strategies such as a blind walking cane or systematic scanning techniques
are other alternatives. Counseling and ancillary care complement above
(for review see (Weiss, 1991)). Genetic counselling poses a particular
challenge (Gross-Jendroska et al., 1992). Dietary supplementation with
vitamin A at a daily dose of 15,000 IU (international units) may slow the
progression of RP in the early stages of the disease (Berson et al., 1993).
Patients should avoid taking vitamin E supplements, because this may
hasten the disease, possibly by reducing the amount of vitamin A reaching
the eye (Berson, 1996). There are a number of controversial treatment
strategies not reviewed here (see (Kalloniatis and Fletcher, 2004; Delyfer
et al., 2004) and references therein). There is experimental evidence an-Review: mesopic vision and disease 10
imals that genetherapy and speciﬁcally gene replacement therapy, may
be an exciting avenue to be pursued (for review see (Rolling, 2004) and
references therein).
Retinitis punctata albescens (RPA) Retinitis punctata albescens (RPA)
is a rare progressive, autosomal recessive disorder caused by a number
of different mutations in a number of genes (Nakamura et al., 2005; Burst-
edt et al., 2005, 2003; Granse et al., 2001; Burstedt et al., 2001, 1999;
Weiss et al., 1992; Morimura et al., 1999; Fishman et al., 2004). The af-
fected genes are the Retinaldehyde–Binding Protein 1 (RLBP1) gene, the
peripherin/RDS gene, the rhodopsin gene. The Arg135Trp point mutation
in the rhodopsin gene was discovered by Souied in 1996 (Souied et al.,
1996) and the RLBP1 mutation was ﬁrst described by Maw in 1997 (Maw
et al., 1997).
Patients usually present in early childhood with night blindness (Naka-
mura et al., 2005; Morimura et al., 1999). As the disease progresses visual
acuity decreases and visual ﬁelds become restricted.
The examination of the fundus demonstrates whitish spots through-
out the fundus (Figure 3), sometimes with a annulus appearance round
the macula (Nakamura et al., 2005; Morimura et al., 1999). With loss
of the nerve ﬁbre layer the retinal vasculature becomes more attenuated
(Morimura et al., 1999).
Fluorescein angiogram may show granular hyperﬂuorescence of the
retina and window defects over the macula (Nakamura et al., 2005).
Optical coherence tomography (OCT) has been used to demonstrate
thinning of the retina around the macula, mainly affecting the outer nuclear
layer (Nakamura et al., 2005).Review: mesopic vision and disease 11
Figure 3: Retinitis punctata albescens, multiple white deposits scattered
throughout the retina are seen alongside macular atrophy. (reproduced
with permission from reference (Spalton et al., 2005)).Review: mesopic vision and disease 12
The ERG is severely abnormal, if not unrecordable for all modalities
(photopic, scotopic and mesopic) (Nakamura et al., 2005; Morimura et al.,
1999). Scotopic blue seems to be particularly vulnerable (Morimura et al.,
1999).
The differential diagnosis includes RP and Nakamura and colleagues
make the point that although the examination of the fundus shows distinc-
tive subretinal ﬂecks in FA, additional genetic analysis may be required
(Nakamura et al., 2005).
Bothnia dystrophy (BD) Bothnia dystrophy (BD) represents a subgroup
of RPA patients with less severe disease due (Burstedt et al., 1999, 2001).
These patients are homozygous for the RLBP1 mutation Arg234Trp and
were from northern Sweden. They have a predilection to exhibit an atrophic-
appearing macular lesion, particularly when over the age of 30.
There is no speciﬁc treatment.
Newfoundland rod-cone dystrophy (NFRCD) Newfoundland rod-cone
dystrophy (NFRCD) represents another subgroup of RP patients with a
particular phenotype due to a mutation in the RLBP1 gene (Eichers et al.,
2002). The onset of the disease is early (< 10 years of age) and rapidly
progresses so that legal blindness is usually reached between the age of
40–50 years. Night blindness is the earliest symptom, followed by progres-
sive loss of peripheral, central and colour vision.
The fundus appearance is somehow distinct to what is observed in RP
or BD. In contrast to RP, there are usually no bone spicule pigmentations
until late in the disease. In contrast to BD the macular appears normal
or shows a “beaten–bronze” atrophy (Eichers et al., 2002). The observedReview: mesopic vision and disease 13
white stippling of the retina and annulus around the macula is similar to
what is observed in RPA.
The rod ERG is affected early in the disease, followed by an abnormal
cone ERG (Eichers et al., 2002).
There is no speciﬁc treatment.
Congenital stationary night blindness (CSNB) Congenital stationary
night blindness (CSNB) is an umbrella term for a heterogeneous, non–
progressive group of disorders presenting in childhood with night blindness
and occasionally other ocular symptoms such as nystagmus, decreased
visual acuity, myopia and hyperopia (Zeitz et al., 2005; Abramowicz et al.,
2005; Weleber, 2002; Wutz et al., 2002; Lorenz et al., 1996). The autoso-
mal dominant variant of CSNB was ﬁrst described in the Nougaret family
by the Belgian ophthalmologist Florent Cunier (Cunier, 1838; JP, 2001)
in collaboration with a local antiquarian (M Chauvet) from a small village
near to Montpelier. The founder of this family was a French butcher by the
name of Jean Nougaret born in Provence in 1636. The Nougaret family
was followed up by Nettleship (Nettleship, 1907).
Whilst many genes are described the underlying biochemical features
are not yet unraveled and more functional studies are needed (Muradov
et al., 2003; Mansergh et al., 2005). There is a recent report of benign
familial myoclonic epilepsy in 3 patients with CSNB suggesting that some
of these patients may suffer from a channelopathy (Manabe et al., 2002)
which is consistent with the ﬁndings in a new animal model (Mansergh
et al., 2005).
The fundus may appear normal, and this variant is referred to as the
Schubert–Bornschein variant (Schubert and Bornschein, 1952).Review: mesopic vision and disease 14
The ERG responses in X–linked and autosomal recessive CSNB show
a selective reduction of the b–wave, whilst the a–wave is almost completely
normal, giving rise to the typical picture of the a–wave being larger than
the b–wave (Miyake et al., 1986, 1994; Bradshaw et al., 2004; Langrova
et al., 2002), a so–called “negative” ERG. Differences in the rod and cone
b–wave responses permit to distinguish CSNB1 from CSNB2 (Zeitz et al.,
2005). The ERG allows for further sub classiﬁcation of the Schubert–
Bornschein variant dependent on whether the defect of the bipolar cells
is complete or incomplete (Schubert and Bornschein, 1952; Miyake et al.,
1986).
The discovery of new phenotypes makes the interpretation of the ERG
more complex and there is no clear genotype phenotype correlation (Ka-
banarou et al., 2004; Allen et al., 2003).
Fundus albipunctatus Fundus albipunctatus (FA), ﬁrst described by Lauber
in 1910 (Lauber, 1910) presents with non–progressive, or very slowly pro-
gressive night–blindness without associated retinal dystrophy. The typical
clinical ﬁndings are multiple whitish yellow spots in the fundus which tend
to be scattered as an annulus around the macular (Figure 4). FA can
present with and without macular atrophy (Nakamura et al., 2003).
FA is caused by a number of distinct mutations in the RDH5 gene which
encodes for the 11-cis retinol dehydrogenase of the retinal pigment epithe-
lium (Nakamura et al., 2003; Nakamura and Miyake, 2002). The biological
function of this enzyme is to oxidises the alcohol 11-cis retinol to the alde-
hyde 11-cis retinal. Impairment of this process results in reduced retinol
delivery and prolonged dark–adaptation.
The interesting ﬁnding is that patients suffer from severely depressedReview: mesopic vision and disease 15
Figure 4: Fundus albipunctatus. The characteristic fundus appearance
with multiple white dots scattered over the retina with macular sparing is
shown (reproduced with permission from reference (Spalton et al., 2005)).Review: mesopic vision and disease 16
rod–function in the early stages of dark adaptation. However, rod function
starts to improve within about 30 minutes of adaptation and returns to near
normal levels after 2–3 hours of adaptation. (Carr et al., 1974). The bio-
chemical basis for this phenomenon is delayed regeneration of rod visual
pigment. It is of note that this also delays the regeneration of cone visual
pigments. In fact cone dysfunction can be demonstrated in about 38% of
patients with FA (Cideciyan et al., 2000; Niwa et al., 2005). Macular lesions
are not required for reduced cone function.
There is no speciﬁc therapy for fundus albipunctatus.
Oguchi disease Oguchi disease is a non–progressive disorder ﬁrst de-
scribed by Oguchi in 1912 (Oguchi, 1912) in which dark adaptation is
8 to 10–times slower than normal (Carr and Ripps, 1967; Sharp et al.,
1990; Cideciyan et al., 1998). Mizuo (Mizuo, 1913) observed in these pa-
tients by examination of the fundus that under light adapted conditions the
retina had a metallic, phosphorescence–like sheen which disappears with
prolonged dark adaptation, a phenomenon which had since carried his
name. Interestingly pigment regeneration appears to be normal despite
a severely reduced dark adaptation (Lamb and Pugh EN, 2004). Oguchi
disease is caused by mutations in genes encoding either of two proteins,
RR or Arr (reviewed in (Dryja, 2000)). These mutations are more common
in the Japanese compared to the European population.
Standard full ﬁeld scotopic ERG shows absent rod responses and a
reduced a–wave. The cone and ﬂicker ERG is normal. The photopic
ERG permits differentiation of patients with Oguchi disease from complete
CSNB where the ON response is reduced (Miyake et al., 1996).Review: mesopic vision and disease 17
2.2 Acquired conditions
Vitamin A deﬁciency (VAD) Vitamin A deﬁciency (VAD), deﬁned by serum
retinol concentration <0.7 mol/L is world wide the most common cause
for xeropthalmia (xeros, dry, ophthalmia, inﬂamed eye) which is followed by
night blindness (Tielsch and Sommer, 1984). Although recognized since
the early Egyptian times (Wolf, 1978), the typical fundus appearance was
not described until 1928 by Uyemura (Uyemura, 1928). Fuchs subse-
quently proposed the name the disease Uyemura syndrome (Fuchs, 1928;
Fuch, 1959).
VAD is a public health issue in countries with part of the population
faces nutritional problems. VAD has recently been described in Afghanistan
(Mihora et al., 2004), Bangladesh (de Pee et al., 2003; Singh and West KP,
2004; Ahmed et al., 2000; Ahmed, 1999), Bhutan (Singh and West KP,
2004), Brazil (Saunders et al., 2004; Ramalho et al., 2002), Cambodia
(Semba et al., 2003; Christian, 2002), Djibouti (Resnikoff et al., 1992),
Ethiopia (Asrat et al., 2002; Haidar and Demissie, 1999), India (Shaw et al.,
2005; Singh and West KP, 2004; Christian, 2002), Indonesia (de Pee et al.,
2003; Singh and West KP, 2004; Mele et al., 1991), Iraq (Al-Kubaisy et al.,
2002), Kenya (Nabakwe et al., 2005), Kiribatie (Schaumberg et al., 1996),
Malaysia (Ngah et al., 2002), Mali (Schemann et al., 2002; Farbos et al.,
2000), the Marshall Islands (Maqsood et al., 2004), Myanmar (Singh and
West KP, 2004), Nepal (Taren et al., 2004; Singh and West KP, 2004),
Niger (Blum et al., 2004), Nigeria (Oso et al., 2003), Philippines (Rosen
et al., 1994), Sri Lanka (Singh and West KP, 2004; Brink et al., 1979), Tan-
zania (Wedner et al., 2000), Thailand (Singh and West KP, 2004; Bloem
et al., 1989), Yemen (Rosen et al., 1996), Zaire (Donnen et al., 1996), Java
(Bergen HR et al., 1988), Malawi (Tielsch et al., 1986). Xerophthalmia re-Review: mesopic vision and disease 18
mains the leading cause of acquired pediatric blindness. The WHO es-
timates that about 140–250 million world wide are at risk of a vitamin A
deﬁciency disorder (Underwood, 2004).
The earliest symptom of VAD is night blindness, followed by peripheral
and central visual ﬁeld constriction (McBain et al., 2005), photophobia,
and reduced visual acuity. The revised WHO (1981) clinical classiﬁca-
tion of xeropthalmia includes night blindness, conjunctival xerosis, Bitot
spots, corneal xerosis, corneal ulceration/keratomalacia, corneal scarring,
xeropthalmia fundus (Sommer, 1982). Photopic stress to the rods can ex-
acerbate night blindness by up regulating the rhodopsin turnover (Baillie,
1816; Stephenson, 1896).
Vitamin A is one of the ﬁve fat–soluble vitamins essential to human
metabolism. Amongst other functions it is needed to synthesize rhodopsin,
the visual pigment used in the rods and cones (McBain et al., 2005).
The differential diagnosis for VAD is wide and apart from patients suf-
fering from malnutrition in the mentioned areas (Mihora et al., 2004; de Pee
et al., 2003; Singh and West KP, 2004; Ahmed et al., 2000; Ahmed, 1999;
Singh and West KP, 2004; Saunders et al., 2004; Ramalho et al., 2002;
Semba et al., 2003; Christian, 2002; Resnikoff et al., 1992; Asrat et al.,
2002; Haidar and Demissie, 1999; Shaw et al., 2005; Singh and West KP,
2004; Christian, 2002; de Pee et al., 2003; Singh and West KP, 2004;
Mele et al., 1991; Al-Kubaisy et al., 2002; Nabakwe et al., 2005; Schaum-
berg et al., 1996; Ngah et al., 2002; Schemann et al., 2002; Farbos et al.,
2000; Maqsood et al., 2004; Singh and West KP, 2004; Taren et al., 2004;
Singh and West KP, 2004; Blum et al., 2004; Oso et al., 2003; Rosen
et al., 1994; Singh and West KP, 2004; Brink et al., 1979; Wedner et al.,
2000; Singh and West KP, 2004; Bloem et al., 1989; Rosen et al., 1996;Review: mesopic vision and disease 19
Donnen et al., 1996; Bergen HR et al., 1988; Tielsch et al., 1986) one
needs to consider diseases such as Crohn disease (Main et al., 1983;
McBain et al., 2005), surgical intervention (McBain et al., 2005; Lee et al.,
2005; Purvin, 1999; Parker et al., 1985) including bowl surgery for se-
vere obesity (McBain et al., 2005; Spits et al., 2004) and eating disorders
(Velasco Cruz et al., 2005), malabsorption (Perlman et al., 1983), alcohol
induced chronic pancreatitis (Ruiz-Martin et al., 2005), cirrhosis (Onder
et al., 2005), a mutation to the plasma retinol binding protein (I41N and
G75D) (Folli et al., 2005; Bennett et al., 2004), common variable immun-
odeﬁciency (Kilic et al., 2005) and pregnancy (Saunders et al., 2004).
VAD can also be observed as a result from acute phase response in-
duced by infection (Nabakwe et al., 2005) in an at risk population (Mihora
et al., 2004; Singh and West KP, 2004; Ahmed et al., 2000; Ahmed, 1999;
Singh and West KP, 2004; Saunders et al., 2004; Ramalho et al., 2002;
Semba et al., 2003; Christian, 2002; Resnikoff et al., 1992; Asrat et al.,
2002; Haidar and Demissie, 1999; Shaw et al., 2005; Singh and West KP,
2004; Christian, 2002; de Pee et al., 2003; Singh and West KP, 2004; Mele
et al., 1991; Al-Kubaisy et al., 2002; Nabakwe et al., 2005; Schaumberg
et al., 1996; Ngah et al., 2002; Schemann et al., 2002; Farbos et al., 2000;
Maqsood et al., 2004; Singh and West KP, 2004; Taren et al., 2004; Singh
and West KP, 2004; Blum et al., 2004; Oso et al., 2003; Rosen et al., 1994;
Singh and West KP, 2004; Brink et al., 1979; Wedner et al., 2000; Singh
and West KP, 2004; Bloem et al., 1989; Rosen et al., 1996; Donnen et al.,
1996; Bergen HR et al., 1988; Tielsch et al., 1986).
The fundus is normal in early VAD, but may later on show multiple white
or grey–white spots in the peripheral retina (Uyemura, 1928), which usually
disappear with vitamin A supplementation (McBain et al., 2005; ApushkinReview: mesopic vision and disease 20
and Fishman, 2005).
The ERG response shows elevated thresholds for both rods and cones,
with the rods being more severely affected (Perlman et al., 1983). In severe
cases the rod ERG can be undetectable. The ERG generally normalizes
with treatment. McBain and colleagues describe an interesting patient who
reported she would see “white as green” and had a selective loss of the
S–cone function (McBain et al., 2005). One of the two cases reported by
Bennett and colleagues was a photographer by profession and reported
that colours appeared as if seen through a yellow ﬁlter, the other patient
reported that colour appeared as if seen through a red screen (Bennett
et al., 2004).
Fluorescein angiography suggests that the white areas in the fundus
represent loss of pigment from the retinal pigment epithelium (Sommer,
1982).
The treatment of VAD is straightforward by supplementing vitamin A.
An interesting new approach using genetically modiﬁed rice and maize
may may eventually contribute enriching vitamin A in the food, but logistic
problems and controversial economical issues need to be addressed (Ed-
itorial, 2005). VAD and xeropthalmia were already known to the ancient
Egyptians and Greeks who treated it with calf’s or goat’s liver which have
a high vitamin A content (Wolf, 1978) (for a historical review see reference
(Wolf, 1996)). However and sadly it needs to be remembered that most of
the children affected by VAD will receive treatment too late to make a full
recovery.
Melanoma associated retinopathy (MAR) Melanoma associated retinopa-
thy (MAR) belongs to the paraneoplastic syndromes and is characterizedReview: mesopic vision and disease 21
by the combination of night blindness, phosophenes (the subjective ap-
pearance of ﬂickering lights), colour deﬁcits on the tritan axis, reduced vi-
sual acuity and central visual ﬁeld loss occurring in patients with metastatic
cutaneous melanoma (Sawyer et al., 1976; Weinstein et al., 1994; Kellner
et al., 1995; Jacobson, 1998; Petzold and Plant, 2005; Pfohler et al., 2003;
Gass, 1984). Visual symptoms frequently start with night blindness and
shimmering, ﬂickering, or pulsating photopsias followed by progressive
loss of visual acuity (Keltner et al., 2001). The occurrance of photopsias is
very sudden and indicative of loss of vision.
Sawyer was probably the ﬁrst to recognize in 1976 the relationship be-
tween a non–ocular cancer and retinal pathology (Sawyer et al., 1976).
Ripps and colleagues were the ﬁrst to describe the occurrence of night
blindness and photopsias in a 30–year old man with melanoma, but they
suggested that toxic properties of the chosen chemotherapy (vincristine)
were causative (Ripps et al., 1984). Generally Gass is accredited for truly
recognizing the MAR syndrome (Gass, 1984).
The mostly accepted pathophysiological mechanism is that (perhaps
in an attempt to limit tumour growth) the human immune-system produces
antibodies which cross–react with bipolar cells of the retina (Milam et al.,
1993; Kellner et al., 1995; Klopfer et al., 1997; Boeck et al., 1997; We-
instein et al., 1994), although this could not be shown in all cases (Fish-
man et al., 1996; Bret-Dibat et al., 1996; Rougier et al., 1995) and cross–
reactivity with other retinal cells is also observed (Keltner et al., 2001).
One group provided some experimental evidence that the transfer of hu-
man IgG from MAR patients into the vitreous of the monkey induces ERG
changes also seen in MAR (Lei et al., 2000).
The fundus has been reported as normal in 19 (44%) of 43 patients. InReview: mesopic vision and disease 22
some cases a pale optic disc, attenuation of retinal vessels including retinal
periphlebitis, changes of pigmentation, occasional vitreous cells (see Table
6 in reference (Keltner et al., 2001)). The inﬂammatory changes may be
more widespread, involving larger parts of the posterior uvea.
Nyctometry (see Assessment, below) is abnormal in MAR patients
(Pfohler et al., 2003). Psychophysical tests suggest a speciﬁc M–cell dys-
function with preservation of P–cell function (Arden et al., 1995).
The ERG typically shows a markedly reduced b–wave due to the de-
funct bipolar cells. A normal A–wave indicates normal functioning of the
photoreceptors (Fishman et al., 1996; Barnes et al., 2002). The ERG pat-
tern resembled the one found in CSNB patients in 54 of 56 patients re-
cently reviewed by Keltner and colleagues (see Table 7 in reference (Kelt-
ner et al., 2001)).
Treatment of the underlying melanoma is the primary concern to the
physician. With regard to the MAR syndrome there are anecdotal reports
that corticosteroids, plasmapheresis, intravenous immunoglobulins (IVIg),
azathioprine, gabapentin, radiation and cytoreductive surgery may be of
some beneﬁt (Guy and Aptsiauri, 1999; Keltner et al., 2001).
Cancer associated retinopathy (CAR) Cancer associated retinopathy
(CAR) is another cancer associated paraneoplastic retinal degeneration
(Sawyer et al., 1976). CAR can be seen with tumors such as pulmonary
small cell carcinoma, breast and other gynecological cancers, endocrine
and other malignancies (Keltner et al., 2001).
The main symptoms are loss of visual acuity associated with photop-
sias which can precede the detection of the cancer by many months. Rod
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peripheral and ring scotomata. Cone dysfunction results in photosensitiv-
ity, decreased colour vision and visual acuity and central scotomata (Kelt-
ner et al., 2001; Petzold and Plant, 2005).
Over 15 different types of antibodies are described with the 23-KDa
protein recoverin being the most commonly found antigen, followed by the
46-KDa protein –enolase and others (i.e. neuroﬁlaments, heat shock
protein 70, TULP1, etc.) (Keltner and Thirkill, 1998; Adamus et al., 2004;
Polans et al., 1995; Thirkill et al., 1992).
The ERG can be abnormal either for cone- or rod–function or for both
presumably dependent upon the proteins targeted by the antibodies.
Treatment of the underlying cancer is the main problem.
Autoimmune-related retinopathy and optic neuropathy (ARRON) syn-
drome Autoimmune–related retinopathy and optic neuropathy (ARRON)
syndrome represents a rare and heterogeneous group of patients with reti-
nal degeneration and optic neuropathy thought to be associated to au-
toimmune antibodies without evidence of cancer, but rather to a systemic
autoimmune disease (Keltner et al., 2001). The symptoms frequently re-
semble those observed in CAR patients. Indeed, antibodies against simi-
lar antigens (i.e. recoverin) are found in ARRON and CAR (Keltner et al.,
2001; Adamus et al., 2004).
The ERG resembles that seen in CAR patients.
No speciﬁc treatment is known and various immunosuppresive strate-
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3 Reduced vision in the mesopic range related
to cone dysfunction
The relevance of cone disease The human retina comprised three types
of cones which in their absorption spectra. The S–cones are most sensi-
tive in the short wavelength spectra, the M–cones in the middle wavelength
spectra and the L–cones in the long wavelength spectra.
Cone disease may cause problems on ﬁrst entering dark.
Enhanced S–cone syndrome (ESCS) Enhanced S–cone syndrome (ESCS)
is a progressive autosomal receptive disorder which can be caused by
a large number of mutations in the NR2ER gene (synonymous to PNR)
(Haider et al., 2000) (for review of these mutations see references (Hayashi
et al., 2005; Wright et al., 2004)). Marmor et al. coined the term ESCS
(Marmor et al., 1990). Inherited retinal dystrophies generally affect the
rods and all three cone types (S–cone, M–cones and S–cones). En-
hanced S–cone syndrome (ESCS) represents a rare exception because
only M- and L–cones are affected, whilst the S–cones or blue cones exist
in excess (Peng et al., 2005). It has been suggested that NR2ER may be
important during retinal development (Bumsted O’Brien et al., 2004; Milam
et al., 2002).
Patients with ESCS suffer from night blindness due to rod dysfunction.
Most young patients suffer from bilaterally reduced visual acuity (VA) to
less than 0.8, which decreases further with age so that by the age of 20
VA generally decreased to less than 0.4 (Nakamura et al., 2004; Sharon
et al., 2003; Nakamura et al., 2002; Yamamoto et al., 1999; Usui et al.,
2004). The peripheral VF is reduced and ring scotomata can be observed
(Hayashi et al., 2005). Colour vision may or may not be impaired depen-Review: mesopic vision and disease 25
dent on severity. The severity and prognosis of ESCS varies from very
mild (Hayashi et al., 2005) to severe (Nakamura et al., 2004), dependent
on the underlying mutation.
The pathognomic ﬁnding in ESCS is the ERG demonstrating “hyper-
function1” of S–cones (Marmor et al., 1990, 2004, 1999; Hood et al., 1995).
The diagnosis of ESCS is frequently based on the typical ﬁndings in the
spectral ERG which combines hypersensitivity to blue stimuli with a hy-
posensitivity to red stimuli (Hayashi et al., 2005; Marmor et al., 1990). In
most patient there is no recordable rod function on ERG, but in very mild
form of ESCS the rod ERG showed low rod b–waves (Hayashi et al., 2005).
The fundus ﬁndings include cystoid changes in the macula and may
also show degenerative changes in the vascular arcade to the mid pe-
ripheral retina. Pigmented spots in degenerating areas can also be seen
(Nakamura et al., 2002; Hayashi et al., 2005; Jurklies et al., 2001; Marmor
et al., 1990).
Optical coherence tomography (OCT) may show large macular retinoschi-
sis and an abnormal laminar retinal architecture (Jacobson et al., 2004;
Hayashi and Kitahara, 2005).
Fluorescein (midphase) may reveal hyperﬂuorescence of the degener-
ative regions and temporal hypoﬂuorescence in areas where pigmented
spots are seen by direct examination of the fundus (Hayashi et al., 2005).
The differential diagnosis of mutations to the NR2E3 gene includes
Goldmann–Favre syndrome (Sharon et al., 2003), autosomal recessive
retinitis pigmentosa (Gerber et al., 2000), and clumped pigmentary retinal
degeneration (Sharon et al., 2003).
1They are probably not truly hyperactive, but just exist in excess resulting in the
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Sorsby fundus dystrophy (SFD) Sorsby fundus dystrophy (SFD) rep-
resents a rare autosomal dominant macular degeneration, ﬁrst described
by Sorsby and Marson in 1949 (Sorsby and Mason, 1949), which presents
with bilateral loss of central vision in the adult. Some patients may present
with nyctalopia prior to the development of the maculopathy (Capon et al.,
1988; Polkinghorne et al., 1989). Pigment dispersion glaucoma is also
observed.
SFD is caused by a mutation on chromosome 22q12-q13 resulting
in decreased activity of TIMP3, the inhibitor to the metaloproteinase 3
(MMP3) (Weber et al., 1994). The condition is progressive (Weber et al.,
1994).
TIMP3 and MMP3 participate in a complex network of enzymes needed
for the normal remodeling of the extracellular matrix (ECM) (Bergers and
Coussens, 2000). The degrading activity of MMPs is high and MMPs are
tightly controlled by their speciﬁc tissue inhibitors (TIMP). A range of dis-
orders has been related to MMPs, but of the TIMPs only TIMP3 has so far
been related to disease (Klenotic et al., 2004). In SFD Ser–Cys mutants
of TIMP3 accumulate in drusen and in Bruch’s membrane similar to what
is seen in the more common age–related macular degeneration (AMD)
(Tabata et al., 1998; Weber et al., 1994; Kamei and Hollyﬁeld, 1999). The
mechanism leading to TIMP3 accumulation remains unknown but is likely
to be related to impaired degradation of the protein (Chong et al., 2003).
Fundus examination in the earlier stages show juxtafoveal choroidal
neovascularization (Barbazetto et al., 2005), diffuse ﬁne yellowish–white
deposits. Retinal hemorrhages may be present (Ayyagari et al., 2000).
Later the picture is dominated by retinal and macular atrophy (Figure 5)
(Atan et al., 2004). Fluorescein angiography shows the classical featuresReview: mesopic vision and disease 27
Figure 5: Sorsby fundus dystrophy, there is widespread RPE atrophy with
an island of RPE preserved centrally. The optic disc is atrophied and the
yellowish–white deposits represent drusen. (reproduced with permission
from reference (Spalton et al., 2005)).
of choroidal neovascularization, that is to say delayed choroidal ﬁlling and
retinal pigment epithelial mottling (Barbazetto et al., 2005; Atan et al.,
2004).
There is no speciﬁc treatment, but retinal neovascularisation may be
limited by photodynamic therapy or steroids (Peiretti et al., 2005; Atan
et al., 2004). On a very short term basis vitamin A supplement may im-
prove the symptoms (Berson, 2000).
The differential diagnosis includes other conditions with early onset reti-
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4 Assessment
The most important, easiest and most economical approach is to ask
the patient if he/she experiences any problems with his/her night vision.
Patients who drive may be particularly aware of impaired vision in the
mesopic range. Accurate and reproducible quantiﬁcation of mesopic vi-
sion and changes in mesopic vision over time are very difﬁcult. Discussion
of the complexities of mesopic photometry is beyond the scope of this re-
view and the interested reader is referred to the paper by Stockman and
Sharpe in this issue. Here we restrict the discussion to some pragmatic
assessments which are relevant for assessment of night driving abilities in
some countries.
Historically the Nyktometer (Rodenstock) was the probably the most
frequently used instrument for assessment of visual acuity under mesopic
conditions (Hartmann and Wehmeyer, 1980; Kolling and Schratz, 1991;
Schlag, 1993). Several developments have been made and the Mesotest
II (Oculus), the Kontrastometer (BKG Medizin Technik GmbH) and the
nyktometer 500 (Rodenstock) may currently be the most frequently used
aparati (Puell et al., 2004; Schlote et al., 1997; Kolling and Schratz, 1991;
, DOG).
The Nyktometer 500 allows for the assessment of monocular and binoc-
ular visual acuity under mesopic conditions using Landolt rings (recom-
mended is the use of plate 505). The forehead is rested against a ﬂexible,
soft plastic cover which shields the eyes from any stray light. It is possible
to keep the spectables on during the test. The aparatus allows to correct
for night myopia by adding minus lenses.
The Mesotest II is very similar to the Nyktometer. One additional fea-Review: mesopic vision and disease 29
ture is that the rear wall of the aparatus can be removed allowing for vision
through a half permeable mirror. The idea is that this may allows to avoid
night myopia. If this option is used care needs to be taken that the apara-
tus points towards a non–light reﬂecting wall and that the illumination in
the room is kept constant.
The Kontrastometer again is very similar to the Nyktometer. An ad-
vantage of this aparatus is that visual acuity is tested using Landolt rings
which are illuminated from behind and also from the side allowing for vari-
ation of contrast which is of use for those patients who suffer from very
poor mesopic vision. Additionally the Landolt rings can be turned so that
the patient cannot memorise the opening position of the ring. The core
features of these three aparati are summarized in Table 1.Review: mesopic vision and disease 30
Table 1: Characteristics of the Nyktometer 500, Mesotest II and Kon-
trastometer (adapted from (, DOG)).
Chasracteristic Nyktometer 500 Mesotest II Kontrastometer
Producer Rodenstock GmbH Oculus Opticger¨ ate BKG Medizin Technik
URL www.rodenstock.com www.oculus.de www.bkg-medizintechnik.de
Optics binocular binocular2 binocular
Field illumination [cd2] 0.032–0.1 0.032–0.1 0.032–0.1
Stimulus presentation pre-programmed3 choice random
Contrast (range) plate dependent4 2:1 – 23:1 1.14:1 – 5:1
Monuclar testing yes yes yes
Correction for night myopia yes yes yes
Other tests include the Pelli–Robson letter contrast sensitivity (Wood
and Owens, 2005), contrast letters (Pesudovs et al., 2004; Smith RA,
1973) and a new automated test developed by Chisholm and Barbur (Chisholm
et al., 2003).
The relationship between mesopic vision and dark–adaptation is of par-
ticular importance for divers, pilots, etc. and a number of tests assess this
function (Plainis et al., 2005; Babizhayev, 2003; Reiner, 1997). Other vi-
sual functions affected by reduced vision in the mesopic range are motion
(Takeuchi et al., 2001) and distance judgment (Bourdy et al., 1991).
Electroretinography (ERG) Electroretinography has a central role in the
diagnosis of all diseases described in the review. It permits testing of rod
function during dark adaptation by providing a white ﬂash of light (scotopic
ERG), cone function adapted to speciﬁc light levels (photopic ERG) and
both rods and cones if a sufﬁciently bright light ﬂash is given under dark
adaptation (mesopic ERG). At intermediate light levels cone function can
be isolated by recording the ERG to rapid ﬂicker or a long wave length
stimulus as the rods will not respond to either of these.
The ERG recordings show an initial negative deﬂection (downwards on
the y–axis) due to closure of cation channels in the outer segment mem-
brane. This is followed by a positive deﬂection (upwards on the y–axis)
due to activity of the photoreceptors and retinal neurons. In this review we
frequently refer to the ERG b–wave which reﬂects the transmission of the
2optional see–through ﬁeld
3Three plates are available: 501, 502 and 505. A potential pitfall with the pre–
programmed presentation is that the patient may memorize the stimulus position which
causes a problem for repeated measurements.
4Plate 501: 1.46:1 – 23:1; plate 502: 1.14:1 – 23:1; plate 505: 2:1 – 23:1.Review: mesopic vision and disease 31
signal from the photoreceptors to the second-order neurons.
In diseases with predominant or early degeneration of rods, pathologi-
cal changes in the scotopic ERG precede those of the photopic ERG. Vice
versa diseases affecting predominantly the cones mainly change the ap-
pearance of the photopic ERG. In cone–rod dystrophy the photopic ERG
is affected ﬁrst, but the scotopic ERG is usually pathological as well. It
needs to be remembered that the standard ERG is not sensitive enough
to detect diseases limited to the macula with a limited amount of cone loss.
5 Conclusions
Impaired vision in the mesopic range is probably the most sensitive and
earliest sign of a range of diseases. Frequently taking a history and ask-
ing for problems with night vision is sufﬁcient to identify affected patients.
Simple tests for assessing mesopic vision have been established and have
been recommended as screening tests particularly for VAD which remains
the most frequent cause for acquired blindness. More detailed tests of
mesopic vision including the nyctometer, ERG, contrast sensitivity, the
psychophysics of the dark adaptation and others contribute unraveling the
function of the visual pathways and their genetic and molecular biological
basis.
It is important to remember that disorders of both the rod and cone
systems can affect vision at mesopic levels. However, relatively little is
known about how the interactions between the two systems, which only
occur at mesopic light levels, can be modiﬁed in disease and how this
may be manifested in the symptomatology. Even less is known about optic
nerve and cerebral disease as in those disorders visual function is almost
exclusively studied under photopic conditions. And yet patients with optic
nerve disease, for example, will often report that they see better in bright
than dim light or vica versa. Patients with bilateral occipital dysfunction
may report that their visual world appears abnormally dark, and that “if
only there were more light” they would be able to see.
The other articles in this issue, and a growing scientiﬁc literature, are
evidence of increasing realisation that mesopic vision is also important in
everyday life of patients, particularly where driving at night is concerned.
In this review we have attempted to provide an understanding of the range
of rod and cone system disorders which may result in impaired vision in
the mesopic range. In the coming years a greater understanding of the
consequences of these and other disorders for mesopic vision will emerge.Review: mesopic vision and disease 32
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